盤中異動 | 藥明生物盤中上漲5%,報於60.7港元
2022年12月29日13時2分,藥明生物(HK02269)盤中上漲5%,報於60.7港元,成交額達11.25億港元,換手率達到0.44%。
12月28日訊,12月28日藥明生物宣佈,其位於愛爾蘭敦多克的生物製藥生產基地(MFG6和MFG7)獲得愛爾蘭健康產品監督管理局(HPRA)GMP認證。這也是該基地的首個生產進口許可(MIA)和臨牀試驗用藥品(IMP)許可,爲提供商業化生產服務奠定堅實基礎。
12月16日,野村:重申藥明生物(02269)“買入”評級,目標價97.78港元。12月1日,中信證券:首予藥明生物(02269)“買入”評級,目標價67港元。
最新的財務數據顯示,公司於2022年1季度,營業收入36.03億人民幣,淨利潤13.11億人民幣;營業收入同比增加63.53%,毛利潤同比增加49.08%,淨利潤同比增加39.22%。
盈立趨勢長盈模型最近一次交易信號,2022年12月28日出現關注信號,觸發價格爲57.8港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.